Aspira Women's Health Appoints Jane Pine Wood to Board of Directors

Aspira Women's Health has appointed Jane Pine Wood to its Board of Directors. Wood brings experience in healthcare, having served as counsel at McDonald Hopkins and chief legal counsel for BioReference Health. She previously built a large laboratory and pathology client portfolio at McDonald Hopkins. Wood will provide valuable expertise as Aspira advances in women's healthcare.

Aspira Women's Health Inc. (QTCQB:AWHL), a bio-analytical based women's health company, has appointed Jane Pine Wood to its Board of Directors, effective July 11, 2025 [1]. The appointment brings significant experience in healthcare and legal aspects to the company, which is focused on delivering leading tools for gynecologic disease diagnostics and management.

Jane Pine Wood, who has served as Counsel at McDonald Hopkins, LLC since 2024, brings a remarkable track record of representing a wide range of healthcare providers. Prior to her role at McDonald Hopkins, she was Chief Legal Counsel for BioReference Health, LLC, a leading clinical diagnostic laboratory specializing in oncology, urology, and women's health. Earlier in her career, Ms. Wood spent nearly three decades as a partner at McDonald Hopkins, where she played a key role in building one of the largest laboratory and pathology client portfolios in the country. She also previously served on the firm's Board of Directors.

The appointment of Ms. Wood is expected to significantly enhance Aspira's growth and drive meaningful change in women's healthcare. The company is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus®, offered to clinicians as OvaSuiteSM, provide a comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. The company's in-development test pipeline will expand its ovarian cancer portfolio and address the need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide.

Aspira's forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, include statements regarding the timing and completion of any products in the development pipeline and the success of the marketing of the OvaSuite portfolio. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors [1].

References:

[1] https://www.bignewsnetwork.com/news/278446604/aspira-women-health-announces-appointment-of-jane-pine-wood-to-the-board-of-directors